ICD-10 Coding for PSA Testing(R97.2, R97.2E, R97.2N)
Learn about PSA testing, including ICD-10 coding guidelines, documentation requirements, and common pitfalls. Ensure accurate and compliant coding for prostate cancer screening and diagnostics.
Complete code families applicable to PSA Testing
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| Z12.5 | Encounter for screening for malignant neoplasm of prostate | Use for asymptomatic patients undergoing routine screening for prostate cancer. |
|
| R97.2 | Elevated prostate specific antigen [PSA] | Use when PSA levels are elevated and further diagnostic workup is needed. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutPSA Testing
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting PSA Testing.
Failing to document PSA levels
Impact
Clinical: Inadequate clinical information for follow-up., Regulatory: Non-compliance with documentation standards., Financial: Potential claim denials.
Mitigation
Always record quantitative PSA results., Include relevant clinical findings.
Using Z12.5 with symptomatic patients
Impact
Reimbursement: Claims may be denied if used incorrectly., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate data on screening practices.
Mitigation
Ensure Z12.5 is only used for asymptomatic screenings.
Screening vs Diagnostic Coding
Impact
Misclassification of screening as diagnostic can lead to audit issues.
Mitigation
Ensure clear documentation of the purpose of the PSA test.